Fanny Jaulin, PhD

Accomplished Oncology Researcher and Innovative Leader

Professional Overview

Fanny Jaulin is an esteemed oncology researcher and leader with a distinguished career spanning over 15 years. As the CEO of Orakl Oncology, a pioneering biotech company, she leverages her extensive expertise in cancer biology and drug development to drive transformative advancements in cancer treatment. Concurrently, Fanny serves as a Principal Investigator at Gustave Roussy, one of the leading comprehensive cancer centers in Europe, and holds a prestigious INSERM Research Director position, further solidifying her impact on the field.

Experience Summary

Current Roles

CEO, Orakl Oncology (2022-Present)

• Provides strategic vision and operational leadership to drive the company's mission of developing innovative cancer therapies

• Oversees all aspects of the company's research and development pipeline, ensuring seamless progression from early-stage discovery to clinical trials

• Fosters a collaborative environment that enables cross-functional teams to achieve ambitious goals and deliver transformative outcomes

Principal Investigator, Gustave Roussy (2012-Present)

• Leads groundbreaking research projects focused on understanding the molecular mechanisms underlying cancer progression and treatment resistance

• Spearheads the development of novel therapeutic approaches, leveraging cutting-edge technologies and interdisciplinary collaborations

• Mentors and guides a team of talented researchers, contributing to the next generation of oncology leaders

INSERM Research Director, Inserm (2025-Present)

• Serves as a distinguished research director, driving innovative research initiatives and shaping the strategic direction of the institute

• Collaborates with leading scientists and clinicians to translate fundamental discoveries into tangible patient benefits

• Secures competitive funding and grants to support the advancement of oncology research

Principal Investigator, RHU ORGANOMIC (2022-Present)

• Leads a multi-disciplinary research program exploring the role of the tumor microenvironment in cancer progression and treatment response

• Develops novel strategies to target the complex interactions within the tumor ecosystem, paving the way for more effective personalized cancer therapies

Career Progression

Prior to her current roles, Fanny held several prestigious positions, including:

• INSERM Research Group Leader (2016-2025)

• ATIP-AVENIR Research Group Leader, CNRS (2012-2017)

• Postdoctoral Fellow, Memorial Sloan Kettering Cancer Center (2009-2012)

• Postdoctoral Associate, Weill Cornell Medical College (2004-2009)

Throughout her career, Fanny has made significant contributions to the field of oncology, driving groundbreaking discoveries and translating research into tangible clinical applications.

Academic Background

Fanny Jaulin holds a PhD in Molecular and Cellular Biology from the University of Paris-Saclay, where she specialized in cancer biology and targeted therapy development. Her doctoral research and subsequent postdoctoral work have been recognized with numerous awards and accolades, including the prestigious AACR-Bayer Innovation and Discovery Award.

Areas of Expertise

• Cancer biology and tumor microenvironment

• Translational oncology and drug development

• Biomarker discovery and personalized medicine

• Interdisciplinary research and collaborative leadership

• Strategic vision and operational excellence

Professional Impact

Fanny's research has been instrumental in advancing the understanding of cancer progression and treatment resistance, leading to the development of innovative therapeutic strategies. Her work has been widely published in prestigious scientific journals, and she is a sought-after speaker at international oncology conferences.

As a trailblazing leader, Fanny has championed cross-functional collaborations, fostering synergies between academia, industry, and clinical practice. Under her guidance, Orakl Oncology has emerged as a prominent player in the oncology landscape, with a robust pipeline of promising drug candidates and a steadfast commitment to improving patient outcomes.

Conclusion

Fanny Jaulin's remarkable career trajectory, anchored in her deep scientific expertise and visionary leadership, positions her as a driving force in the field of oncology. Her unwavering dedication to translating research into tangible patient benefits, coupled with her ability to inspire and guide high-performing teams, make her a valuable asset in the quest to conquer cancer.